Moffitt Cancer Center and Fulgent Pharma have announced a strategic partnership to enhance the development of personalised cancer therapies.
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Anixa Biosciences and its partner Moffitt Cancer Center have initiated treatment of the first subject in the Phase I clinical trial of new chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center (Moffitt).
Newswise — TAMPA, Fla. — Drugs that target specific proteins have greatly improved patient outcomes across a broad range of tumor types; however, patients often develop drug resistance and tumor recurrence. There is a great unmet need to identify new targets that could be used for drug development. In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers report their identification of a new target for the PARP inhibitor drug talazoparib and show that combination treatment with talazoparib and the WEE1 inhibitor adavosertib results in enhanced anti-cancer effects.